Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) Operating Expenses (2016 - 2025)

ProQR Therapeutics' Operating Expenses history spans 5 years, with the latest figure at $123.1 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 34.75% to $123.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $71.8 million, a 36.07% increase, with the full-year FY2025 number at $69.6 million, up 30.22% from a year prior.
  • Operating Expenses hit $123.1 million in Q4 2025 for ProQR Therapeutics, up from -$16.6 million in the prior quarter.
  • Over the last five years, Operating Expenses for PRQR hit a ceiling of $127.9 million in Q4 2022 and a floor of -$20.9 million in Q3 2022.
  • Historically, Operating Expenses has averaged $8.4 million across 5 years, with a median of -$14.4 million in 2021.
  • Biggest five-year swings in Operating Expenses: surged 729.12% in 2022 and later plummeted 69.5% in 2025.
  • Tracing PRQR's Operating Expenses over 5 years: stood at -$20.3 million in 2021, then soared by 729.12% to $127.9 million in 2022, then plummeted by 40.88% to $75.6 million in 2023, then increased by 20.83% to $91.4 million in 2024, then surged by 34.75% to $123.1 million in 2025.
  • Business Quant data shows Operating Expenses for PRQR at $123.1 million in Q4 2025, -$16.6 million in Q3 2025, and -$18.4 million in Q2 2025.